A.L.I. and SonoSite form marketing alliance
SonoSite customers who purchase the company’s handheld ultrasound devices will be able to use A.L.I. Technology’s image management and networking products to network film printers or filmless image management systems, under a nonexclusive
SonoSite customers who purchase the companys handheld ultrasound devices will be able to use A.L.I. Technologys image management and networking products to network film printers or filmless image management systems, under a nonexclusive agreement.
A.L.I. is a medical information technology company based in Richmond, BC, that markets medical digital imaging products. Bothell, WA-based SonoSite manufactures inexpensive, handheld, digital ultrasound systems. It was spun off from ATL Ultrasound and became an independent public company in April 1998.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
